Search | Clinical Trials Finder

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Revefenacin, Tiotropium, Revefenacin Placebo, Tiotropium Placebo; Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 40 Years and older
Enrollment: 404 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 76
States / cities: Jasper, Alabama • Phoenix, Arizona • Tucson, Arizona + 67 more

Conditions: Chronic Obstructive Pulmonary Disease, Chronic Bronchitis
Interventions: 7% hypertonic saline; Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 82 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: COPD Exacerbation
Interventions: Revefenacin (YUPELRI) & Formoterol (Perforomist), Albuterol Inhalation Aerosol (short-acting beta-agonists) & Ipratropium Aerosol (short-acting anticholinergic); Drug
Lead sponsor: University of Tennessee Graduate School of Medicine; Other
Eligibility: 40 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Asthma
Interventions: T-Piece Nebulizer, Breath-Enhanced Nebulizer, Albuterol, Pre-Treatment Spirometry Measurement, Post-Treatment Spirometry Measurement; Device · Drug · Procedure
Lead sponsor: Seton Healthcare Family; Other
Eligibility: 6 Years to 17 Years
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Albuterol Sulfate, 2.5 Mg/3 mL (0.083%) Inhalation Solution, Vibrating Mesh Nebulizer, Metered Dose Inhaler, Jet Nebulizer; Drug · Device
Lead sponsor: Polarean, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Chronic Obstructive Pulmonary Disease - COPD
Interventions: Formoterol fumarate (6 μg), Formoterol furmarate (20 μg), Placebo for formoterol fumarate, Formoterol fumarate (12 μg), Formoterol fumarate (40 μg); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 130 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 20
States / cities: Glendale, Arizona • Phoenix, Arizona • Tempe, Arizona + 17 more

Conditions: COPD
Interventions: Ensifentrine, Placebo; Drug
Lead sponsor: Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 3
States / cities: Birmingham, Alabama • Ann Arbor, Michigan • Pittsburgh, Pennsylvania

Conditions: COPD Exacerbation
Interventions: Revefenacin, formoterol fumarate, Placebo (Sterile Normal Saline), Albuterol sulfate, Ipratropium Bromide; Drug · Other
Lead sponsor: University of Tennessee Graduate School of Medicine; Other
Eligibility: 40 Years and older
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Respiratory Distress Syndrome, Adult
Interventions: Albuterol Sulfate, Mini-Bronchoalveolar Lavage (BAL), Placebo; Drug · Procedure
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 13 Years and older
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 40
States / cities: Fresno, California • Sacramento, California • San Francisco, California + 19 more

Conditions: Asthma
Interventions: Jet Nebulizer, Vibrating Mesh Nebulizer; Device
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 2 Years to 18 Years
Enrollment: 220 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Heart Failure, Cardiomyopathy
Interventions: Inhaled nebulized milrinone; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 2
States / cities: Kansas City, Kansas • Nashville, Tennessee

Conditions: Hypoxemic Respiratory Failure, Airway Obstruction
Interventions: nebulizer via in-line drug delivery maintaining high-flow nasal cannula oxygen, standard jet nebulization (SJN) with face mask; Device
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Los Angeles, California • Santa Monica, California

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Glycopyrrolate (85 μg), Glycopyrrolate (42.5 μg), Glycopyrrolate (14 μg), Placebo; Drug
Lead sponsor: Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 7
States / cities: Clearwater, Florida • Tampa, Florida • Saint Charles, Missouri + 4 more

Conditions: Non-cystic Fibrosis Bronchiectasis
Interventions: Nebulized Ensifentrine Suspension; 3 mg, Nebulized Placebo Solution; Drug
Lead sponsor: Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 284 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 29
States / cities: Birmingham, Alabama • Los Angeles, California • Sacramento, California + 26 more

Conditions: Asthma Exacerbation
Interventions: Aeroneb nebulizer, Small volume jet nebulizer; Device
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years to 55 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Respiratory Insufficiency
Interventions: Vibrating Mesh Nebulizer Arm, Jet Nebulizer Arm; Device
Lead sponsor: Rush University Medical Center; Other
Eligibility: 1 Year and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Idiopathic Pulmonary Arterial Hypertension.
Interventions: Albuterol., Normal saline placebo; Drug
Lead sponsor: American Medical Association Foundation; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Ensifentrine 3 mg, Glycopyrrolate 42.5 mcg, Ensifentrine 1.5 mg, Ensifentrine 3 mg (marketed formulation); Drug
Lead sponsor: Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 4
States / cities: Clearwater, Florida • Tampa, Florida • Saint Charles, Missouri + 1 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Ensifentrine 3 mg, Glycopyrrolate 21.25 mcg, Glycopyrrolate 42.5 mcg, Placebo; Drug
Lead sponsor: Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 497 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 57
States / cities: Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 49 more

Conditions: MAC Lung Disease, Treatment Refractory MAC Lung Disease, Mycobacterium Infections, Nontuberculous
Interventions: Clofazimine Inhalation Suspension, Placebo; Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 54
States / cities: Birmingham, Alabama • Fresno, California • Los Angeles, California + 47 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Arformoterol tartrate inhalation solution, Tiotropium; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 55 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 28
States / cities: Birmingham, Alabama • Flagstaff, Arizona • Waterbury, Connecticut + 24 more

Conditions: Asthma
Interventions: VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System (AKITA JET) with mouthpiece, VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System (AKITA JET) with facemask, 1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with mouthpiece, 1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with facemask, 0.5 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with mouthpiece, 0.5 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with facemask; Combination Product
Lead sponsor: Vectura Limited; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 2
States / cities: Tempe, Arizona • Anaheim, California

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Vibrating Mesh Nebulizer, Jet Nebulizer; Device
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 40 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Bronchiectasis Adult, Mediastinal Lymphadenopathy, Pneumonia, Chest--Diseases, Infiltrates, Bronchopulmonary Disease, Cancer, Lung
Interventions: Topical lidocaine, Nebuliser solution, Nebuliser Suspension; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Search by objective public record fields.

Phase 4 COPD and Suboptimal Inspiratory Flow Rate

Mucus Dehydration and Evolution of Chronic Obstructive Pulmonary Disease (COPD) Lung Disease

Feasibility, Safety and Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Hospitalized Patients With AECOPD

Comparison of Breath-Enhanced and T-Piece Nebulizers in Children With Acute Asthma

Comparison of Bronchodilator Response From Three Different Aerosol Delivery Methods in Patients With COPD Using Hyperpolarized Xe 129 MRI Ventilation Imaging

Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)

Effect of Ensifentrine on Sputum Markers of Inflammation in COPD

Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Patients Presenting to the Emergency Department With Acute Exacerbation of COPD (ECOPD)

Drug Study of Albuterol to Treat Acute Lung Injury

Comparison of Vibrating Mesh Nebulizer Versus Jet Nebulizer in the Pediatric Asthma Patient

Nebulized Inhaled Milrinone in a Hospitalized Advanced Heart Failure Population

In Line Aerosol Nebulization With High Flow

A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD

A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis

Effectiveness of the Aeroneb in Acute Severe Asthma

RCT of Mesh Versus Jet Nebulizers on Clinical Outcomes During Mechanical Ventilation in the Intensive Care Unit

Albuterol and Dynamic Hyperinflation in Idiopathic Pulmonary Arterial Hypertension

A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease

A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD

ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension

A Study of Arformoterol Tartrate Inhalation Solution and Tiotropium Bromide on Re-hospitalization in Chronic Obstructive Pulmonary Disease (COPD) Subjects

A Comparison of VR647 and Conventionally Nebulized Budesonide in Healthy Volunteers and Adult Asthma Subjects

Medicated Aerosol Delivery Using A Jet Nebulizer Versus A Vibrating Mesh Nebulizer in COPD Exacerbation

Lidocaine Administration During Flexible Bronchoscopy and Endobronchial Ultrasound